SCNI - Scinai Immunotherapeutics Company Cash Volume

Can Scinai Immunotherapeutics (SCNI) overcome low pricing power within the CDMO segment? Exclusive nanobody patents and powerful lobbying serve as a defense, creating barriers for competitors. Revenues are based on the development of biologics for infection therapy. The amount of cash on the balance sheet clearly demonstrates financial stability, while the value of 0.00 captures the level of the company's liquid reserve metric.
Analytical breakdowns and data insights for company Scinai Immunotherapeutics Ltd (SCNI)

Scinai Immunotherapeutics (SCNI) invests in the development of nanobodies for the therapy of chronic skin pathologies. This indicator measures the volume of liquid assets required to cover operating expenses until the commercialization of patents. The investor analyzes the burn rate to assess the risk of default or the necessity of a secondary offering. An optimal cash balance prevents capital stagnation. The company's cash history clearly demonstrates business resilience during the development period.